Teva Pharmaceutical Industries revenue and financials
$39.13Change from previous close: −1.34%Absolute change: −$0.53
In the fiscal year ended December 2025, Teva Pharmaceutical Industries reported revenue of $17.26B (+4.32% year over year). Net income was $1.41B, a net margin of 8.2%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.32%
- 2025 vs 2024
- Net margin
- 8.2%
- 2024: -9.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 411 | -40.0 | 1,158 | 369 | 227 | — |
| Depreciation and amortization | 241 | 239 | 260 | 249 | 251 | — |
| Capital expenditure | -104 | -168 | -142 | -136 | -96.0 | — |
| Investing cash flow | -491 | 229 | 165 | 135 | 236 | — |
| Financing cash flow | -1.0 | 13.0 | 40.0 | -453 | 6.0 | — |
| Debt issued | 0.0 | — | 0.0 | — | 2,305 | — |
| Debt repaid | 0.0 | -23.0 | 0.0 | -451 | -2,300 | — |
| Effect of exchange rates | -5.0 | -17.0 | -10.0 | -9.0 | -5.0 | — |
| Net change in cash | -81.0 | 202 | 1,363 | 51.0 | 469 | — |
| Free cash flow | 307 | -208 | 1,016 | 233 | 131 | — |